BEACON: A randomised, phase 3 study of encorafenib and cetuximab plus /- binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer patients
Wasan, H Arkenau, T Braun, Michael S Samuel, L Graham, J Kopetz, S Grothey, A Van Cutsem, E Yaeger, R Yoshino, T
Wasan, H
Arkenau, T
Braun, Michael S
Samuel, L
Graham, J
Kopetz, S
Grothey, A
Van Cutsem, E
Yaeger, R
Yoshino, T
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Wasan H, Arkenau T, Braun MS, Samuel L, Graham J, Kopetz S, et al. BEACON: A randomised, phase 3 study of encorafenib and cetuximab plus /- binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer patients. British Journal of Cancer. 2019;121:24